BMS 986184
Alternative Names: BMS-986184Latest Information Update: 14 Oct 2023
At a glance
- Originator Bristol-Myers Squibb
- Class Monoclonal antibodies
- Mechanism of Action Chemokine CXCL10 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Ulcerative colitis
Most Recent Events
- 14 Oct 2023 Discontinued - Phase-I for Ulcerative colitis in Australia (IV)
- 14 Oct 2023 Discontinued - Phase-I for Ulcerative colitis in Georgia (IV)
- 14 Oct 2023 Discontinued - Phase-I for Ulcerative colitis in Moldova (IV)